Терапия хронической обструктивной болезни легких: возможности индакатерола

Княжеская Н.П. Терапия хронической обструктивной болезни легких: возможности индакатерола. Consilium Medicum. 2014; 16 (11): 13–17.

Читать PDF

Аннотация

Число пациентов, страдающих хронической обструктивной болезнью легких (ХОБЛ), значительно выше, чем зарегистрировано в лечебных учреждениях. Поздняя диагностика ХОБЛ – одна из актуальных проблем, так как при ранних стадиях болезни пациенты долгое время считают себя здоровыми людьми, а ее симптомы (кашель, отделение мокроты и появление одышки при физической нагрузке) объясняют другими причинами. Следует подчеркнуть, что ХОБЛ является не только большой медицинской проблемой, но и крайне сложной социальной проблемой, заключающейся в высокой степени социальной дезадаптации пациентов преимущественно пожилого возраста. Одно из центральных мест в фармакотерапии ХОБЛ занимают бронхолитики, применение которых позволяет уменьшить выраженность одышки и увеличить толерантность к физической нагрузке. В настоящее время в клинической практике стал широко применяться представитель класса b2-агонистов с быстрым и ультрадлительным (24-часовым) действием – индакатерол (Онбрез® Бризхалер®). Важной особенностью препарата является высокая кардиобезопасность. Применение препарата Онбрез® Бризхалер® позволит снизить количество обострений, увеличить толерантность к физической нагрузке, повысить качество жизни пациентов с ХОБЛ.
Ключевые слова: хроническая обструктивная болезнь легких, толерантность к физической нагрузке, гиперинфляция, индакатерол, интервал QT, b2-агонисты ультрадлительного действия.

________________________________________________

The number of patients suffering from COPD is much higher than reported in hospitals. Late diagnosis of COPD is one of their current problems, as in the early stages of the disease for a long time, patients consider themselves healthy, and the symptoms (such as cough, sputum production and the emergence of dyspnea on exertion) are often attributed to other causes. It should be emphasized that COPD is not only a great health problem but also an extremely complex social problem as the high degree of social exclusion of patients is present, mostly in elderly people. A central place in the pharmacotherapy of COPD is taken by bronchodilators, the use of which reduces the severity of dyspnea and increased exercise tolerance. Currently in clinical practice a class of βb2 - agonists with fast and ultra-long (24-hour) action such indacaterol (Onbrez® Breezhaler®) has gained a wider use. An important feature of the drug is its high level of cardiac safety. Use of Onbrez® Breezhaler® will reduce the number of exacerbations, as well as increase exercise tolerance and improve the quality of life of patients with COPD.
Key words: COPD, exercise tolerance, hyperinflation, indacaterol, interval QT, βb2-agonists, ultra-long-acting.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. http://www.goldcopd.org/
2. European Lung Foundation. COPD Burden in Europe. 2009 www.european-lung-foundation.org
3. Lopez AD, Shibuya K, Rao C et al. Chronic Obstructive Lung Disease: current burden and future projections. Eur Respir J 2006; 27 (1): 188–207.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349 (9064): 1498–504.
5. Респираторная медицина. Руководство. Под ред. А.Г.Чучалина. М.: ГЭОТАР-Медиа, 2007.
6. Anthonisen NR, Connett JE, Murray RP and The Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–9.
7. Чучалин А.Г. Система оксиданты и антиоксиданты и пути коррекции. Пульмонология. 2004; 4: 111–5.
8. Соодаева С.К. Роль свободнорадикального окисления в патогенезе ХОБЛ. Атмосфера. Пульмонология и аллергология. 2000; 5: 27–31.
9. Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22 (1): 101–11.
10. Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med 2006; 119: 32–7.
11. Waschki B, Kirsten A, Holz O et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140 (2): 331–42.
12. Rytila P, Rehn T, Ilumets H et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006; 28 (7): 69.
13. Dellacà RL, Pompilio PP, Walker PP et al. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009; 33 (6): 1329–37.
14. Thomas M et al. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22 (1): 101–11; Rossi review 2014.
15. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: astatement of the American Thoracic Society and European Respiratory Society. American Thoracic Society, European Respiratory Society. Am J Respir Crit Care Med 1998; 158: 629–34.
16. Naline E, Trifilieff A, Fairhurst RA et al. Effect of indacaterol, a novel long-acting b2-adrenoceptor agonist, on human isolated bronchi. Eur Respir J 2007; 29: 575–81.
17. Battram C, Charlton SJ, Cuenoud B et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled b2-adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762–70.
18. Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled b2-adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008; 324: 270–5.
19. Mihăltan F. Indacaterol – a new hope for maximising bronchodilation? Pneumologia 2011; 60 (1): 21–5.
20. Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009; 38 (5): 533–47.
21. Beeh KM, Beier J. The short, the long and the «ultra-long»: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010; 27 (3): 150–9.
22. Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 mg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11.
23. Kornmann O, Dahl R, Centanni S et al. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD:
a placebo-controlled comparison. Eur Respir J 2011; 37 (2): 273–9.
24. Dahl R, Chung K F, Buhl R et al. On behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily, long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473–9.
25. Donohue JF, Fogarty C, Lötvall J et al. INHANCE Study Investigators.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182 (2): 155–62.
26. O’Donnell DE, Casaburi R, Vincken W et al. INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011; 105 (7): 1030–6.
27. Watz H, Krippner F, Kirsten A et al. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease – a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med 2014; 14: 158.
28. Rennard S, Bantje T, Centanni S et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102: 1033–44.
29. Khindri S, Sabo R, Harris S et al. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011; 26 (11): 31.
30. Milic M, Bao X, Rizos D et al. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation. Clin Ther 2006; 28: 582–90.
31. Worth H, Chung KF, Felser JM et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105: 571–9.
32. Pascoe S, Reynolds C, Pleskow W et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily b2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther 2011; 49: 153–61.
33. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043–8.
34. Partridge MR, Schuermann W, Beckman O et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1–11.
35. Wedzicha JA, Dahl R, Buhl R et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014; 108 (10): 1498–507.

Авторы

Н.П.Княжеская

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва

________________________________________________

N.P. Knyazheskaya

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.